Cobenfy Karxt
Memory Loss
University of Texas Southwestern Medical CenterEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Memory Loss cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Madopar Peking University Third Hospital | Phase 4 | BB |
Prometrium | Phase 3 | B |
Dfn-15 University of California, Los Angeles | Phase 3 | B |
Metformin University of Pennsylvania | Phase 2 | B |
Strattera Icahn School of Medicine at Mount Sinai | Phase 2 | B |
View all 20 →
Same molecule, other indications
Cobenfy Karxt is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →